Radhika Tripuraneni - 23 Feb 2022 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)

Reporting relationship: Chief Development Officer
Issuer ticker: PRTA
Reported as of: 23 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Feb 2022, 20:31:10 UTC
Next SEC filing: 28 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael Malecek as Attorney in Fact for Radhika Tripuraneni

Key filing fact

Radhika Tripuraneni filed Form 4 for PROTHENA CORP PUBLIC LTD CO (PRTA) on 25 Feb 2022.

Key facts

This page summarizes Radhika Tripuraneni's Form 4 filing for PROTHENA CORP PUBLIC LTD CO (PRTA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 Feb 2022, 20:31.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRTA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 23 Feb 2022
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 50,000
Exercise price: $32.45
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 23, 2023 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.